Abstract
Five growth retarded children with Down's syndrome, three girls and two boys aged between 3 1/2 and 6 1/2 years with trisomy 21, were treated with human growth hormone for six months. Before treatment the growth hormone response to sleep and insulin-arginine load, as well as serum concentrations of insulin, thyroid hormones, and cortisol was found to be in the normal range. During the treatment with human growth hormone the growth velocity increased in all the children with Down's syndrome from 2.3-2.8 cm to 3.3-5.8 cm per six months. The serum concentrations of immunoreactive insulin like growth factor 1 (IGF-1) were low before treatment and increased during the treatment with human growth hormone. The serum concentrations of immunoreactive insulin like growth factor 2 (IGF-2), which were within the normal range, however, increased during treatment with human growth hormone. Children with Down's syndrome respond to treatment with human growth hormone, with an increase in both growth velocity and serum somatomedin concentrations.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Annerén G., Enberg G., Sara V. R. The presence of normal levels of serum immunoreactive insulin-like growth factor 2 (IGF-2) in patients with Down's syndrome. Ups J Med Sci. 1984;89(3):274–278. doi: 10.3109/03009738409179508. [DOI] [PubMed] [Google Scholar]
- Hall K., Brandt J., Enberg G., Fryklund L. Immunoreactive somatomedin A in human serum. J Clin Endocrinol Metab. 1979 Feb;48(2):271–278. doi: 10.1210/jcem-48-2-271. [DOI] [PubMed] [Google Scholar]
- Hall K., Enberg G., Ritzén M., Svan H., Fryklund L., Takano K. Somatomedin A levels in serum from healthy children and from children with growth hormone deficiency or delayed puberty. Acta Endocrinol (Copenh) 1980 Jun;94(2):155–165. doi: 10.1530/acta.0.0940155. [DOI] [PubMed] [Google Scholar]
- Hall K., Sara V. R. Growth and somatomedins. Vitam Horm. 1983;40:175–233. doi: 10.1016/s0083-6729(08)60435-5. [DOI] [PubMed] [Google Scholar]
- Hayek A., Peake G. T. Growth and somatomedin-C responses to growth hormone in dwarfed children. J Pediatr. 1981 Dec;99(6):868–872. doi: 10.1016/s0022-3476(81)80008-x. [DOI] [PubMed] [Google Scholar]
- Laron Z., Pertzelan A., Karp M., Kowadlo-Silbergeld A., Daughaday W. H. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone: measurement of sulfation factor, metabolic and linear growth responses. J Clin Endocrinol Metab. 1971 Aug;33(2):332–342. doi: 10.1210/jcem-33-2-332. [DOI] [PubMed] [Google Scholar]
- Merimee T. J., Zapf J., Froesch E. R. Dwarfism in the pygmy. An isolated deficiency of insulin-like growth factor I. N Engl J Med. 1981 Oct 22;305(17):965–968. doi: 10.1056/NEJM198110223051701. [DOI] [PubMed] [Google Scholar]
- Rudman D., Kutner M. H., Blackston R. D., Cushman R. A., Bain R. P., Patterson J. H. Children with normal-variant short stature: treatment with human growth hormone for six months. N Engl J Med. 1981 Jul 16;305(3):123–131. doi: 10.1056/NEJM198107163050302. [DOI] [PubMed] [Google Scholar]
- Ruvalcaba R. H., Thuline H. C., Kelley V. C. Plasma growth hormone in patients with chromosomal anomalies. Arch Dis Child. 1972 Apr;47(252):307–309. doi: 10.1136/adc.47.252.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sara V. R., Gustavson K. H., Annerén G., Hall K., Wetterberg L. Somatomedins in Down's syndrome. Biol Psychiatry. 1983 Jul;18(7):803–811. [PubMed] [Google Scholar]
- Sara V. R., Sjögren B., Annerén G., Gustavson K. H., Forsman A., Hall K., Wahlström J., Wetterberg L. The presence of normal receptors for somatomedin and insulin in fetuses with Down's syndrome. Biol Psychiatry. 1984 Apr;19(4):591–598. [PubMed] [Google Scholar]